UK diagnostics company Owlstone Medical was among winners of a $1 million award that will help develop new devices for patients with idiopathic pulmonary fibrosis (IPF).
Patients stand to benefit from moves to replace conventional paper-based drug product information with an electronic system compatible with smartphones and computers, a conference heard.
